Age: 14.0
Sex: F
Vaccine: HPV4
Symptoms: Amenorrhoea, Anti-Muellerian hormone level decreased, Autoimmune disorder, Autonomic neuropathy, Blood follicle stimulating hormone increased
Clinical narrative: autoimmune reaction againts the ovary/ heterogenous autoimmune injuries; autonomic injuries; neurological injuries; premature ovarian failure/ amenorrhea, very elevated follicle stimulating and luteinizing hormone levels, and extremely lowlevels of anti-mullerian hormones / hot flashes / irregularities in her menses; Information has been received from a lawyer regarding a case in litigation and refers to an adolescent (reported as adult, discrepant information) female patient (pt). Her medical history, concurrent conditions and concomitant therapies were not provided. On 19-JUL-2016, at the age of 14 years old, the pt was vaccinated with the first dose of quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) intramuscular injection (exact dose, route of administration, anatomical location, lot # and expiration date were not provided), as recommended by physician (referred to as a doctor and also as a health care provider), with her mother's consent, for prophylaxis (also reported as "touted as a safe and effective vaccine for preventing cervical cancer"). On 01-SEP-2016, she was vaccinated with the second dose of quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) intramuscular injection, and on 05-JAN-2017, she received the third dose of quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) intramuscular injection (exact dose, route of administration, anatomical location, lot # and expiration date were not provided was both), both for prophylaxis. On unknown dates, the pt experienced autonomic, neurological and heterogenous autoimmune injuries. On 01-MAR-2017 (reported as in Spring 2017), the pt noticed irregularities in her menses. By that summer, she began to experience hot flashes. On 08-DEC-2018, the pt was seen by a physician for amenorrhea, who noted that her presentation suggested an autoimmune reaction against the ovary as opposed to primary ovarian failure. On 18-FEB-2019, the pt was diagnosed with ovarian failure based on amenorrhea, very elevated follicle stimulating and luteinizing hormone levels, and extremely low levels of anti-mullerian hormone. Prior to receiving quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL)  vaccine, the pt did not suffer from amenorrhea, ovarian failure, any autoimmune disorder, or any other serious disability. Based upon her chronic and severe post- quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) symptoms, the pt was diagnosed with premature ovarian failure. The pt contended that her quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) injections caused her to develop serious and debilitating injuries, including but not limited to autoimmune disease, as well as a constellation of adverse symptoms, complications, injuries, and other adverse events, many of which were alleged herein and all of which were caused by quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) or otherwise linked to her quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) induced autoimmune disorder. As a proximate result of quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL), the pt suffered and continued to suffer severe and permanent physical injuries and associated symptomology and suffered severe and permanent emotional injuries, including pain and suffering. She also had a substantial fear of suffering additional and ongoing harms, including but not limited to being at an increased risk of cancer, and future symptoms and harms associated with her autoimmune disease and other injuries caused by quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL). As a direct and proximate result of her quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL)-induced injuries, the pt suffered and continued to suffer economic losses, including considerable financial expenses for medical care and treatment, and diminished income capacity, and she would continue to incur these losses and expenses in the future. The outcome of the events was considered to be not recovered/not resolved. The reporter considered all the events to be related to human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL).  Upon internal review, autoimmune disorder and autonomic neuropathy were determined to be medically significant.  The reporter considered all events to be disabling.